Unicycive Therapeutics faces securities class action tied to oxylanthanum phosphate binder NDA statements
UNCY•A securities class action filed Sept. 3, 2026, in federal court in California alleges violations tied to Unicycive’s public statements about its NDA for oxylanthanum carbonate. The company called the allegations meritless and said it plans to fight the case.
1. Lawsuit filed
The suit names Unicycive Therapeutics and certain officers, alleging federal securities law violations tied to public statements about its NDA for oxylanthanum carbonate. The claims concern the phosphate binder’s use to treat hyperphosphatemia in chronic kidney disease patients on dialysis.
